Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center were awarded a four-year, $2.6 million grant from the US FDA to conduct an innovative Phase I clinical trial of a new drug for patients with relapsed and treatment-resistant forms of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
[Albert Einstein College of Medicine]
